XM does not provide services to residents of the United States of America.
S
S

Stryker


News

Teleflex beats quarterly profit estimates on strong demand for medical devices

CORRECTED-Teleflex beats quarterly profit estimates on strong demand for medical devices Corrects revenue estimate in paragraph 3 to $768.7 million from$768.7 billion Feb 22 (Reuters) - Teleflex TFX.N reported fourth-quarter profit above Wall Street estimates on Thursday, on the back of strong demand for its medical devices and surgical equipment.
S
T

Medical device maker Baxter beats sales and profit estimates on strong demand

Medical device maker Baxter beats sales and profit estimates on strong demand Feb 8 (Reuters) - Baxter International BAX.N beat Wall Street expectations for fourth-quarter sales and profit on Thursday on strong demand for its medical devices and improvements in the supply chain environment. Expectations around performance of medical device makers have increased over the past month after health insurers flagged higher medical costs as people, especially older adults, undergo medical procedures th
S

S&P 500 top and bottom performing stocks at about 03:30 p.m. EST

BUZZ - S&P 500 top and bottom performing stocks at about 03:30 p.m. EST S&P 500 .SPX Top Performers Percent Change Paramount Global PARA.OQ +7.4% Stryker Corp SYK.N +7.1% Edwards Lifesciences Corp EW.N +6.3% Boeing Co BA.N +5.4% Fortive Corp FTV.N +5.1% Bottom Performers Percent Change Marketaxess Holdings Inc MKTX.OQ -17.4% Rockwell Automation Inc
B
G
T
U
S
F
M

U.S. STOCKS Boeing, Mondelez International, Novavax

BUZZ-U.S. STOCKS ON THE MOVE-Boeing, Mondelez International, Novavax Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The tech-heavy Nasdaq tumbled to more than a week low on Wednesday, as Alphabet's projections for rising AI costs dented most megacap and chip stocks ahead of a crucial U.S.
A
B
G
M
M
M
M
M
N
Q
S
T
T
A
A
U
U
S
T

Stryker hits record high on upbeat 2024 forecast, brokerages raise PT

BUZZ-Stryker hits record high on upbeat 2024 forecast, brokerages raise PT ** Shares of medical device maker Stryker Corp SYK.N rise 6.6% to $337.59, a record high ** Co on Tuesday forecast 2024 profit above Wall Street estimates, upbeat Q4 results ** Sees 2024 adj EPS to be $11.70-$12.00 vs analysts' estimates of $11.56 - LSEG ** At least 10 brokerages raise PT on co ** Deutsche Bank raises PT to $345 from $300; Jefferies raises PT to $390 from $345 ** Big Q4 beat sets the stage for a strong 20
S

Stryker Corp reports results for the quarter ended in December - Earnings Summary

Stryker Corp reports results for the quarter ended in December - Earnings Summary Stryker Corp SYK.N reported quarterly adjusted earnings of $3.46​​ per share for the quarter ended in December, higher than the same quarter last year, when the company reported EPS of $3.00. The mean expectation of twenty six analysts for the quarter was for earnings of $3.27 per share.
S

Stryker rises on upbeat 2024 forecast, Q4 results above estimates

BUZZ-Stryker rises on upbeat 2024 forecast, Q4 results above estimates ** Shares of Stryker Corp SYK.N rise 3.9% to $329 in extended trading ** Co forecasts 2024 adj EPS to be $11.70-$12.00 vs Wall Street estimates of $11.56 - LSEG ** SYK's Q4 adj EPS $3.46 beats avg analysts' estimate of $3.27 ** Med-tech firm's Q4 rev of $5.8 bln beats estimates
S

Stryker forecasts strong 2024 as uptick in surgeries lift demand for devices

Stryker forecasts strong 2024 as uptick in surgeries lift demand for devices Jan 30 (Reuters) - Stryker Corp SYK.N forecast 2024 profit above Wall Street estimates on Tuesday, banking on a post-pandemic pick-up in volume for certain surgical procedures at hospitals to drive sales for its medical and surgical devices. Shares of the med-tech firm rose 3.2% to about $327 after the bell.
S

Stryker Q4 Adjusted EPS USD 3.46 Vs. IBES Estimate USD 3.27

BRIEF-Stryker Q4 Adjusted EPS USD 3.46 Vs. IBES Estimate USD 3.27 Jan 30 (Reuters) - Stryker Q4 revenue USD 5,800 million vs. IBES estimate USD 5,601 million. Q4 EPS USD 2.98 Q4 net income USD 1,100 million Q4 adjusted gross margin 63.9% Q4 adjusted net income USD 1,300 million vs. IBES estimate USD 1,255 million Q4 adjusted EBIT margin 27.2% outlo
S

Refunding fuel, megacaps update, China ailing

MORNING BID AMERICAS-Refunding fuel, megacaps update, China ailing Jan 30 (Reuters) - A look at the day ahead in U.S. and global markets from Mike Dolan Spurred by falling estimates of U.S. Treasury borrowing , a sweep of megacap earnings updates and this week's upcoming Federal Reserve decision, Wall St. stocks and bonds have surged anew - in stark contrast to another slide in China's ailing markets.
G
M
M
P
S
T
A
J
U
U
S
A

Stryker Corp <SYK.N> expected to post earnings of $3.27 a share - Earnings Preview

Stryker Corp expected to post earnings of $3.27 a share - Earnings Preview Stryker Corp SYK.N , SYK is expected to show a rise in quarterly revenue when it reports results on January 30 for the period ending December 31 2023 The Kalamazoo Michigan-based company is expected to report a 7.6% increase in revenue to $5.598 billion from $5.2 billion a year ago, according to the mean estimate from 22 analysts, based on LSEG data.
S

J&J profit edges past Street view after deals delay Stelara competition

UPDATE 6-J&J profit edges past Street view after deals delay Stelara competition Adds analyst comment in paragraphs 12-13 and 17, adds CEO quote in paragraph 16 By Bhanvi Satija and Patrick Wingrove Jan 23 (Reuters) - Johnson & Johnson JNJ.N on Tuesday reported quarterly results just above Wall Street expectations, helped by strong sales of its blockbuster psoriasis drug Stelara, which is expected to face fresh U.S.
A
G
S

U.S. STOCKS Halozyme, Scorpio Tankers

BUZZ-U.S. STOCKS ON THE MOVE-Halozyme, Scorpio Tankers Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes fell on Tuesday after mixed earnings from Morgan Stanley and Goldman Sachs pressured banks, while declines in Boeing and Apple also weighed.
A
A
C
F
M
N
P
T
A
W
U
U
S
U

Piper Sandler sees 'positive' macro environment for medtech

BUZZ-Piper Sandler sees 'positive' macro environment for medtech ** Brokerage Piper Sandler raises targets on many medtech companies, including Boston Scientific BSX.N Teleflex TFX.N and Stryker SYK.N ** Says, it recommends Alphatec Holdings ATEC.O and DexCom DXCM.O , with DexCom as its favorite pick of the year ** "We anticipate some concern around the political backdrop here in the U.S.
S
T

U.S. Centerspace, Dutch Bros, Fortinet

U.S. RESEARCH ROUNDUP-Centerspace, Dutch Bros, Fortinet Jan 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Centerspace, Dutch Bros, and Fortinet, on Tuesday. HIGHLIGHTS * Centerspace CSR.N : RBC raises to outperform from sector perform * Dutch Bros Inc BROS.N : Stifel raises to buy from hold * Fortinet Inc FTNT.O : Wells Fargo cuts to equal weight from overweight * Rocket Companies Inc RKT.N : Citigroup cuts to se
A
A
B
C
C
C
C
F
I
J
N
V
A
W
A
K
S
A
A
A
M
T

Stryker Announces 2023 Sales Surpassed $20 Bln

BRIEF-Stryker Announces 2023 Sales Surpassed $20 Bln Jan 8 (Reuters) - Stryker Corp SYK.N : STRYKER ANNOUNCES 2023 SALES SURPASSED $20 BILLION Source text for Eikon: ID:nGNX64n63p Further company coverage: SYK.N
S

U.S. STOCKS Greenbrier, Abercrombie & Fitch

BUZZ-U.S. STOCKS ON THE MOVE-Greenbrier, Abercrombie & Fitch Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The benchmark S&P 500 and the Nasdaq rose on Friday after services sector data pointing to a weaker economy raised bets of faster interest-rate cuts this year, hours after robust jobs data doused expectations of rapid easing.
A
A
C
H
A
L
A
G
W
U
U
S
H
M

U.S. STOCKS CVS Health, Peloton, Eli Lilly

BUZZ-U.S. STOCKS ON THE MOVE-CVS Health, Peloton, Eli Lilly Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes edged higher on Friday as gains in megacap stocks outweighed pressure from a stronger-than-expected jobs report that tempered expectations of rapid interest rate cuts this year.
A
A
C
P
L
G
W
U
U
S
C
H

Medtechs to see 'exciting' 2024 - Bernstein

BUZZ-Medtechs to see 'exciting' 2024 - Bernstein ** Brokerage Bernstein says a large number of product catalysts and multiple new launches make 2024 an "exciting" year for the medtech market ** Elective procedures and hospital staffing are gradually approaching pre-COVID trendline and will contribute to medtech growth - Brokerage ** Brokerage also
A
S

Stryker Announces Dr. Srikant Datar Will Retire From Board Of Directors

BRIEF-Stryker Announces Dr. Srikant Datar Will Retire From Board Of Directors Dec 6 (Reuters) - Stryker Corp SYK.N : STRYKER ANNOUNCES DR. SRIKANT DATAR WILL RETIRE FROM BOARD OF DIRECTORS Source text for Eikon: ID:nGNX5GPkkl Further company coverage: SYK.N
S



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.